|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM359378870 |
| 003 |
DE-627 |
| 005 |
20240330000406.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202300665
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1355.xml
|
| 035 |
|
|
|a (DE-627)NLM359378870
|
| 035 |
|
|
|a (NLM)37437039
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Yi, Ke
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Engineered Nanomaterials to Potentiate CRISPR/Cas9 Gene Editing for Cancer Therapy
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 29.03.2024
|
| 500 |
|
|
|a Date Revised 29.03.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2023 Wiley‐VCH GmbH.
|
| 520 |
|
|
|a Clustered regularly interspaced short palindromic repeats/associated protein 9 (CRISPR/Cas9) gene-editing technology shows promise for manipulating single or multiple tumor-associated genes and engineering immune cells to treat cancers. Currently, most gene-editing strategies rely on viral delivery; yet, while being efficient, many limitations, mainly from safety and packaging capacity considerations, hinder the use of viral CRISPR vectors in cancer therapy. In contrast, recent advances in non-viral CRISPR/Cas9 nanoformulations have paved the way for better cancer gene editing, as these nanoformulations can be engineered to improve safety, efficiency, and specificity through optimizing the packaging capacity, pharmacokinetics, and targetability. In this review, the advance in non-viral CRISPR delivery is highlighted, and there is a discussion on how these approaches can be potentially used to treat cancers in addressing the aforementioned limitations, followed by the perspectives in designing a proper CRISPR/Cas9-based cancer nanomedicine system with translational potential
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a CRISPR/Cas9
|
| 650 |
|
4 |
|a cancer therapy
|
| 650 |
|
4 |
|a drug delivery
|
| 650 |
|
4 |
|a gene editing
|
| 650 |
|
4 |
|a nanomaterials
|
| 700 |
1 |
|
|a Kong, Huimin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lao, Yeh-Hsing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Di
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mintz, Rachel L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fang, Tianxu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Guojun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tao, Yu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Mingqiang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ding, Jianxun
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 13 vom: 14. März, Seite e2300665
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:13
|g day:14
|g month:03
|g pages:e2300665
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202300665
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 2024
|e 13
|b 14
|c 03
|h e2300665
|